

Osteoporosis: risk assessment, treatment and prevention of fragility fractures Committee meeting 11

Date: 30/07/2024

Location: Virtual (Zoom)

Minutes: Final

Committee members present:		
Alison Tedstone (Chair)		(Present for notes 1 – 6)
Nicola Peel (Topic adviser)		(Present for notes 1 – 7)
Alison Ahmed		(Present for notes 1 – 7)
Irene Baker		(Present for notes 1 – 7)
Sherwin Criseno		(Present for notes 1 – 7)
Elaine Dennison		(Present for notes 1 – 7)
Paul Hamilton		(Present for notes 1 – 7)
Iain Macleod		(Present for notes 5 – 7)
Kay Morgan		(Present for notes 1 – 7)
Rachel Muir		(Present for notes 1 – 7)
Nicholas Pipkin		(Present for notes 1 – 7)
Karen Whitehead		(Present for notes 1 – 7)

In attendance:		
Annette Chalker	Technical Analyst	(Present for notes 1 – 7)
Sarah Glover	Information Specialist	(Present for notes 1 – 7)
Amber Hernaman	Project Manager	(Present for notes 1 – 7)
Bernard Higgins	Clinical Advisor	(Present for notes 1 – 7)
Clare Jones	Senior Technical Analyst	(Present for notes 1 – 7)
Kate Lovibond	Senior Health Economist	(Present for notes 1 – 7)
Maria Majeed	Technical Analyst	(Present for notes 1 – 7)
Qudsia Malik	Senior Technical Analyst	(Present for notes 1 – 7)
Lisa Miles	Technical Analyst	(Present for notes 1 – 7)
Eric Power	Deputy Director (Centre for Guidelines)	(Present for notes 1 – 4)
Muksitur Rahman	Health Economist	(Present for notes 1 – 7)
Carlos Sharpin	Guideline Lead	(Present for notes 1 – 7)

Apologies:

Nick Staples	Guideline Commissioning Manager
Stuart Ralston	Committee member
Karen Knapp	Committee member
Rajesh Varma	Committee member
Rebecca Boucher	Editor
Suzie Panek	Resource Impact

1. Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to the 11th Osteoporosis guideline committee. The Committee members and attendees introduced themselves.

The Chair informed the Committee that apologies had been received. These are noted above.

The Chair outlined the objectives of the meeting, which included.

- Pharmacological treatments update
- VFRAC Diagnostic Accuracy and Effectiveness of VFRAC
- Exercise protocol
- Risk assessment and resource impact of DXA update

2. Confirmation of matter under discussion, and declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was strategy for monitoring.

The Chair asked everyone to verbally declare any interests that had arisen since the last meeting. Declarations of interest are noted below.

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Alison Ahmed	Lead Specialist Pharmacist in Rheumatology, Tameside and Glossop Integrated Care NHS Foundation	Received honorarium from Amgen pharmaceutical company, as an adviser on Ustekinumab biosimilar biological	Financial interest	Declare and participate.

	Trust	medicines. (Not related to Osteoporosis, or osteoporosis medication)		
Alison Ahmed	Lead Specialist Pharmacist in Rheumatology, Tameside and Glossop Integrated Care NHS Foundation Trust	Royal Osteoporosis Society Medication Support Programme: 'A programme aimed to support informed decisions for people advised to take osteoporosis medicines, by developing a digital programme that provides professional support and information'. Invited as a healthcare professional to contribute to development of this digital programme.	Non-financial professional and personal interest	Declare and participate.
3. Minutes of last meeting				
Agreed.				
4. Pharmacological treatment update				
Eric Power (Deputy Director for the Centre for Guidelines at NICE) attended for this section of the meeting to update the committee on the pharmacological review and Technology Appraisal incorporation.				
5. Evidence reviews				
Annette Chalker and Muksitur Rahman presented the clinical and health economics evidence to the committee.				
6. Protocols				
Clare Jones presented the exercise protocol to the committee and Amber Hernaman made edits on the day.				
7. AOB				

None.

Date of next meeting: 23/09/2024

Location of next meeting: Zoom